التفاصيل البيبلوغرافية
| العنوان: |
НОВИ ФАРМАКОТЕРАПЕВТИЧНИ ПОДХОДИ ЗА ЛЕЧЕНИЕ НА ХРОНИЧНАТА СЪРДЕЧНА НЕДОСТАТЪЧНОСТ С РЕДУЦИРАНА ФРАКЦИЯ НА ИЗТЛАСКВАНЕ. (Bulgarian) |
| العنوان البديل: |
NEW PHARMACOTHERAPEUTIC OPTIONS FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION. (English) |
| المؤلفون: |
Хвърчанова, Н., Стоева, Ст., Радева-Илиева, М., Георгиева, М. |
| المصدر: |
Medical Review - Cardiovascular Diseases; 2021, Vol. 52 Issue 2, p9-17, 9p |
| مصطلحات موضوعية: |
TREATMENT effectiveness, TREATMENT failure, VENTRICULAR ejection fraction, SODIUM-glucose cotransporter 2 inhibitors, SYMPTOMS, HEART failure |
| مستخلص: |
Heart failure (HF) is a complex clinical syndrome of great social significance. Over the last three decades, substantial progress has been made in the treatment of heart failure with reduced ejection fraction (HFrEF). New pharmacological therapies have proven benefits on patient morbidity, mortality and quality of life. Several new pharmacotherapeutic approaches for the treatment of HFrEF have demonstrated in clinical trials that they provide further improvement in outcomes in patients receiving standard HFrEF therapy. These new medications are sacubitril/valsartan, SGLT2 inhibitors, vericiguat and omecamtiv mecarbil. According to resent studies, sacubitril/valsartan and SGLT2 inhibitors (dapagliflozin and empagliflozin) are useful and well tolerated by most hospitalized patients and may be part of HFrEF basic treatment. Other medications (vericiguat and omecamtiv mecarbil) have shown promising results in reducing the risk of hospitalizations for HF or cardiovascular mortality in patients with more severe or advanced HF. These drugs may be important for the treatment of high-risk patients with HFrEF, whose symptoms persist or worsen, despite optimal guideline treatment. Advances in the pharmacotherapy of comorbidities such as diabetes, iron deficiency/anemia, and hyperkalemia are also significant, as they further improve outcomes in patients with HF. The aim of this review is to summarize the scientific evidence on the efficacy and safety of new pharmacological therapies for HFrEF, with an emphasis on the perspective of their inclusion in clinical practice. [ABSTRACT FROM AUTHOR] |
|
Copyright of Medical Review - Cardiovascular Diseases is the property of Medical University - Sofia, Central Medical Library and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
